RTK Inhibitors in Melanoma: From Bench to Bedside

RTK Inhibitors in Melanoma: From Bench to Bedside

MAPK (mitogen activated protein kinase) and PI3K/AKT (Phosphatidylinositol-3-Kinase and Protein Kinase B) pathways play a key role in melanoma progression and metastasis that are regulated by receptor tyrosine kinases (RTKs). Although RTKs are mutated in a small percentage of melanomas, several rece...

Full description

Bibliographic Details
Main Authors: Malak Sabbah, Ahmad Najem, Mohammad Krayem, Ahmad Awada, Fabrice Journe, Ghanem E. Ghanem
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
RTKs
RTK inhibitors
resistance
drug combination
melanoma
c-KIT
Online Access:https://www.mdpi.com/2072-6694/13/7/1685

Internet

https://www.mdpi.com/2072-6694/13/7/1685

Similar Items